Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 6, 2026, 3:38 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1441–1464 of 5,232 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Infection Clear all

Conditions: Wound Infection, Abscess, Systemic Inflammation, Cellulitis
Interventions: Single-Dose IV Oritavancin Diphosphate, IV Vancomycin, Placebo; Drug
Lead sponsor: Melinta Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 968 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 1
States / cities: Chula Vista, California

Conditions: Respiratory Syncytial Virus (RSV)
Interventions: RSVpreF MDV, RSVpreF SDV; Biological
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 49 Years · Female only
Enrollment: 453 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024
U.S. locations: 6
States / cities: South Miami, Florida • Stockbridge, Georgia • Idaho Falls, Idaho + 3 more

Conditions: Rhinosinusitis
Interventions: FinESS Sinus Treatment; Device
Lead sponsor: Entellus Medical, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 74 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 13
States / cities: Fresno, California • Denver, Colorado • Trumbull, Connecticut + 10 more

Conditions: HIV
Interventions: HXTC infusion; Biological
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 18 Years to 65 Years
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Urinary Tract Infections
Interventions: Urine PCR testing; Diagnostic Test
Lead sponsor: David Sheyn; Other
Eligibility: 60 Years and older
Enrollment: 96 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: COVID-19 Infection
Interventions: Clazakizumab, Placebo; Drug
Lead sponsor: The Methodist Hospital Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Houston, Texas

Conditions: HIV-1 Infection
Interventions: DOR/ISL, BIC/FTC/TAF, Placebo to BIC/FTC/TAF, Placebo to DOR/ISL; Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older
Enrollment: 599 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2025
U.S. locations: 17
States / cities: Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 14 more

Conditions: Home Parenteral Nutrition
Interventions: Caregiving support interventions (FamTechCare); Behavioral
Lead sponsor: University of Kansas; Other
Eligibility: 18 Years and older
Enrollment: 172 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2011
U.S. locations: 1
States / cities: Kansas City, Kansas

Conditions: Infection, Bacterial, Infection Viral
Interventions: Adult and Pediatrics; Other
Lead sponsor: Beckman Coulter, Inc.; Industry
Eligibility: 90 Days to 89 Years
Enrollment: 650 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 4
States / cities: Indianapolis, Indiana • Baltimore, Maryland • Boston, Massachusetts + 1 more

Conditions: HIV Infections
Interventions: Itraconazole; Drug
Lead sponsor: Janssen, LP; Industry
Eligibility: 18 Years and older
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 1
States / cities: Buffalo, New York

Conditions: Herpes Simplex, HIV Infections, Hepatitis B
Interventions: Fialuridine; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 13 Years to 65 Years
Enrollment: 78 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 1993
U.S. locations: 4
States / cities: Birmingham, Alabama • San Diego, California • Bethesda, Maryland + 1 more

Conditions: HIV Infections
Interventions: TMC-114; Drug
Lead sponsor: Tibotec Pharmaceuticals, Ireland; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 202
States / cities: Anniston, Alabama • Birmingham, Alabama • Mesa, Arizona + 199 more

Conditions: Erosive Esophagitis, Heartburn, Symptomatic Nonerosive Gasroesophageal Reflux Disease, Helicobacter Pylori Infection
Interventions: Vonoprazan; Drug
Lead sponsor: Phathom Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 15 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024
U.S. locations: 1
States / cities: Las Vegas, Nevada

Conditions: Traumatic Brain Injury
Interventions: Blood/saliva sampling; Other
Lead sponsor: The University of Texas Health Science Center, Houston; Other
Eligibility: 18 Years to 70 Years
Enrollment: 96 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2016
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Hematopoietic Stem Cell Transplant, Poor Marrow Graft Function
Interventions: Donor peripheral blood progenitor cells: stimulation, harvesting, isolation and T-cell depletion, CliniMACS Cell Selection System; Procedure · Device
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: Not listed
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 1
States / cities: New York, New York

Conditions: Meningococcal Meningitis, Meningococcal Infections
Interventions: Test Vaccine, US Licensed Vaccine; Biological
Lead sponsor: JN-International Medical Corporation; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 525 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2014
U.S. locations: 3
States / cities: Greenbelt, Maryland • Pasadena, Maryland • Towson, Maryland

Conditions: Tularaemia
Interventions: Placebo, Undiluted Francisella tularensis live attenuated vaccine; Other · Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 45 Years
Enrollment: 228 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2012
U.S. locations: 5
States / cities: Decatur, Georgia • Iowa City, Iowa • Baltimore, Maryland + 2 more

Conditions: Lumbar Spinal Stenosis
Interventions: Not listed
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 50 Years to 90 Years
Enrollment: 239 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2023
U.S. locations: 7
States / cities: Denver, Colorado • Decatur, Georgia • Ann Arbor, Michigan + 4 more

Conditions: HIV Infections
Interventions: Not listed
Lead sponsor: Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections; Network
Eligibility: 13 Years and older
Enrollment: 5,982 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2013
U.S. locations: 75
States / cities: Birmingham, Alabama • Los Angeles, California • Menlo Park, California + 46 more

Conditions: Urinary Tract Infections
Interventions: Hiprex; Drug
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 50 Years to 85 Years · Female only
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Lower Respiratory Tract Infections
Interventions: Next Generation Genomic Sequencing; Other
Lead sponsor: Pediatric Blood and Marrow Transplant Foundation, Inc.; Other
Eligibility: Up to 21 Years
Enrollment: 250 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2016
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Head and Neck Cancer, Precancerous Condition
Interventions: cetuximab, intensity-modulated radiation therapy (IMRT), Paclitaxel, Cisplatin; Biological · Radiation · Drug
Lead sponsor: Eastern Cooperative Oncology Group; Network
Eligibility: 18 Years and older
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2015
U.S. locations: 121
States / cities: Birmingham, Alabama • Greenbrae, California • Palo Alto, California + 86 more

Conditions: Urinary Tract Infection, Head Injury, Laceration
Interventions: Video discharge instructions; Other
Lead sponsor: George Washington University; Other
Eligibility: 18 Years and older
Enrollment: 193 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: Washington D.C., District of Columbia

Conditions: Cytomegalovirus Infections, HIV Infections
Interventions: Zidovudine, Ganciclovir; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 1990
U.S. locations: 3
States / cities: San Diego, California • New York, New York • Rochester, New York

Search by objective public record fields.

Oritavancin Versus IV Vancomycin for the Treatment of Participants With Acute Bacterial Skin and Skin Structure Infection (SOLO I)

A Study to Assess Safety, Tolerability and Immunogenicity of RSVpreF From Multidose Vials in Healthy Female Adults.

Healthcare Utilization and Outcomes of FinESS Treatment in the Office

Phase I Study of HIV 1 Antigen Expanded Specific T Cell Therapy

Urine Gene Analysis for Pathogen Detection

Clazakizumab vs. Placebo - COVID-19 Infection

Study of Doravirine/Islatravir (DOR/ISL 100 mg/0.75 mg) to Evaluate the Antiretroviral Activity, Safety, and Tolerability in Treatment-Naïve Participants With Human Immunodeficiency Virus Type 1 (HIV-1) Infection (MK-8591A-020)

Technological Home Care: Improving HPN Care With Videophone And Internet Education

Access MeMed BV Assay Clinical Study Collection Protocol - Infectious Adult and Pediatric Cohorts

Study of Itraconazole in Patients With Advanced HIV Infection

The Tolerance of HIV-Infected Patients With Herpes Group Virus Infections to Oral Doses of FIAU

TMC114-C226: An Early Access Program to Evaluate the Long-term Safety and Tolerability of TMC114 Combined With a Low Dose of Ritonavir (TMC114/r) With Other Antiretrovirals, for HIV-1 Infected Patients Who Have Failed Multiple Antiretroviral Regimens.

A Study to Evaluate Vonoprazan Concentrations in Breast Milk of Healthy Lactating Women Receiving Vonoprazan 20 mg Once Daily or Vonoprazan 20 mg Twice Daily

A Pilot Study to Identify Biomarkers Associated With Chronic Traumatic Brain Injury

T-cell Depleted Hematopoietic Stem Cell Boosts Without Conditioning for Poor Marrow Graft Function Following Allogeneic Hematopoietic Stem Cell Transplantation

Immunogenicity and Safety of Group A, C, Y & W-135 Meningococcal Polysaccharide Diphtheria Toxoid Conjugate Vaccine

Phase II Tularemia Vaccine Comparison

Predictors of Decompressive Laminectomy Outcomes

Long-Term Data Collection From Participants in Adult AIDS Clinical Trials

Efficacy and Mechanism of Action of Methenamine Hippurate (Hiprex™) in Women With Recurring Urinary Tract Infections.

Pathogen Identification in Pediatric Hematopoietic Stem Cell Transplant Patients With Suspected Lower Respiratory Tract Infection

Induction Chemotherapy Followed By Cetuximab and Radiation in HPV-Associated Resectable Stage III/IV Oropharynx Cancer

Video Discharge Instructions (VDI) as Adjuncts to Written Discharge Instructions in the Emergency Department

A Study of AZT Plus Ganciclovir in Patients With AIDS and Cytomegalovirus (CMV) Infection